Law, Lucy http://orcid.org/0000-0002-8129-8771
Lindqvist, Per http://orcid.org/0000-0002-8192-9166
Liv, Per http://orcid.org/0000-0002-5494-8134
Hellman, Urban http://orcid.org/0000-0002-3822-0725
Lejon, Kristina http://orcid.org/0000-0001-5025-6539
Geijer, Mats http://orcid.org/0000-0003-0529-7723
Söderberg, Stefan http://orcid.org/0000-0001-9225-1306
Forsblad-d’Elia, Helena http://orcid.org/0000-0001-7871-5303
Funding for this research was provided by:
Vetenskapsrådet
Västerbotten's Association Against Rheumatism
The Swedish Association Against Rheumatism
Region Västerbotten
Stiftelsen Konung Gustaf V:s 80-årsfond
The Norrlands Heart Foundation
Mats Klebergs Stiftelse
Umea University
Article History
Received: 29 November 2023
Revised: 12 February 2024
Accepted: 15 February 2024
First Online: 6 March 2024
Declarations
:
: The regional Ethical Review Board at Umeå University, Sweden, approved this study (Patients with r-axSpA; 2015/352–31, 2016/208–31, controls; 2020–01813) which was performed in accordance with the Declaration of Helsinki.
: All patients included in the Backbone Study and control subjects gave written informed consent.
: Consent for publication has been obtained from all authors. See attached disclosure form.
: L.L, P. Ld, P.Lv, U.H, K.L and HFdE have declared no conflicts of interest. S.So reports consultancy and speakers honoraria from Actelion Ltd. P. Ld reports consultancy and speakers honoraria from Pfizer. MG reports speakers bureau Abbvie and UBC.